Artiva Biotherapeutics, Inc., a clinical stage company whose mission is to deliver highly effective, off-the-shelf, allogeneic natural killer (NK) cell-based therapies that are safe and accessible to cancer patients, announced today that an abstract highlighting further in vivo and in vitro preclinical data for AB-101, the Company’s clinical-stage ADCC-enhancer product candidate, was accepted for presentation at the Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting, to be held virtually and at the Boston Convention & Exhibition Center from November 8 to 12, 2022.
Details of the presentation are as follows:
Title: Evaluation of AB-101, an Allogeneic Cord Blood-derived Natural Killer (NK) Cell Therapy, as an ADCC Enhancer in Hematologic and Solid Tumors
Poster Number: 306
Date: Friday, November 11
Time: 9:00 a.m. to 8:30 p.m. ET
Location: Boston Convention & Exhibition Center in Hall C
The abstract will be available for viewing on November 7 at 8:00 am EST at the Journal for Immunotherapy of Cancer (JITC) website (JITC link to be provided on the SITC Annual Meeting website at https://www.sitcancer.org/2022/home). The poster will also be available for viewing on November 10 at 9:00 am EST at https://www.sitcancer.org/2022/home.
The poster will present data on the universal use of an ADCC-enhancer NK cell, AB-101, in combination with ADCC-mechanistic therapeutic antibodies and will describe a broader set of antibody combinations beyond rituximab. Artiva is conducting a Phase 1/2 clinical trial (ClinicalTrials.gov Identifier: NCT04673617) to assess the safety and clinical activity of AB-101 alone and in combination with the anti-CD20 monoclonal antibody, rituximab, in patients with relapsed or refractory B-cell-non-Hodgkin lymphoma (NHL) who have progressed beyond two or more prior lines of therapy.
About Artiva Biotherapeutics
Artiva’s mission is to deliver highly effective, off-the-shelf, allogeneic NK cell-based therapies utilizing our Manufacturing-First approach, that are safe and accessible to cancer patients. Artiva’s pipeline includes AB-101, an ADCC enhancer NK-cell therapy candidate for use in combination with monoclonal antibodies or innate-cell engagers. Artiva is currently advancing a Phase 1/2 clinical trial of AB-101 in combination with rituximab for the treatment of relapsed or refractory B-cell lymphomas. Artiva’s pipeline also includes AB-201, an anti-HER2 CAR-NK cell therapy candidate for the treatment of HER2-overexpressing tumors, such as breast, gastric, and bladder cancers, and for which an IND has been allowed by FDA, and AB-202, a CD19-specific CAR-NK cell therapy candidate for the treatment of B-cell malignancies. Artiva has entered into therapeutic NK cell collaborations with Merck Sharp & Dohme Corp. and with Affimed GmbH. Artiva’s AlloNK™ platform incorporates cell expansion, activation, and engineering technology developed by Artiva’s strategic partner, GC Cell Corporation, a member of the GC family of companies, a leading healthcare company in Korea. Artiva is headquartered in San Diego. For more information, visit www.artivabio.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20221005005287/en/
Contacts
Media: Jessica Yingling, Ph.D., Little Dog Communications Inc., jessica@litldog.com, +1.858.344.8091
Investors: Michael E. Faerm, Artiva Biotherapeutics, ir@artivabio.com
